Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BCG + MMC: Adding Mitomycin C to BCG as Adjuvant Intravesical Therapy for High-risk, Non-muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial

NCT06462001 is registered in ClinicalTrials.gov with Nottingham University Hospitals NHS Trust as lead sponsor.

NCT NCT06462001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06462001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BCG + MMC: Adding Mitomycin C to BCG as Adjuvant Intravesical Therapy for High-risk, Non-muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial
Lead sponsor
Nottingham University Hospitals NHS Trust
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 10, 2020
Completion date
December 1, 2026
Enrollment
500 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

transitional cell carcinoma, transurethral resection